newsfilter
← Earnings
Earnings Releases·

C4 Therapeutics — Third Quarter 2026 Earnings Summary

C4 Therapeutics reported a net loss of $21.8 million for the third quarter of 2026, with total revenue declining to $8.5 million from $11.2 million in the prior year period. The company's cash position stood at $274.7 million as of September 30, 2026, which is projected to fund operations through the end of 2028. Clinically, the Phase 2 MOMENTUM trial for cemsidomide is on track to complete enrollment in the first quarter of 2027, with initial overall response rate data expected in the second half of 2027. Additionally, a Phase 1b trial evaluating cemsidomide in combination with elranatamab has advanced to new dose escalation cohorts, with data from all evaluated cohorts anticipated in mid-2027.

Company
C4 THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology